Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROVOCHOLINE vs DUVOID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Parasympathomimetic agent that acts as a direct cholinergic agonist at muscarinic receptors, increasing exocrine gland secretion.
Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in the bladder neck and prostate, reducing outflow resistance.
FDA: Diagnosis of bronchial airway hyperreactivity in subjects without clinically apparent asthma.,Off-label: Treatment of xerostomia, glaucoma.
Benign prostatic hyperplasia (BPH) - treatment of symptoms,Off-label: None established
Subcutaneous: 2.5-5 mg; if no response, repeat with 5-10 mg; maximum single dose 10 mg.
100 mg orally three times daily.
Terminal elimination half-life is 1-2 hours in patients with normal renal function. However, due to rapid hydrolysis by plasma and tissue cholinesterases, the actual duration of effect is brief (minutes). Clinical context: half-life may be prolonged in patients with reduced cholinesterase activity or renal impairment.
Terminal elimination half-life is 12–15 hours in patients with normal renal function; prolonged to 24 hours or more in moderate-to-severe renal impairment.
Primarily metabolized by acetylcholinesterase.
Extensively metabolized in the liver primarily by CYP2D6 and CYP3A4, with possible minor contributions from other CYPs.
Primarily renal excretion of unchanged drug and inactive metabolites. Approximately 80-90% of administered dose is excreted renally. No significant biliary or fecal elimination.
Renal elimination accounts for approximately 90% of a dose as unchanged drug; biliary/fecal excretion is minor (<10%).
Very low protein binding (<5%). Does not significantly bind to albumin or other plasma proteins.
Approximately 50–70% bound to plasma proteins, primarily albumin.
Approximately 0.1-0.2 L/kg. Small Vd indicates limited extravascular distribution, consistent with a quaternary ammonium compound that does not readily cross cell membranes or the blood-brain barrier.
Vd approximately 0.6 L/kg, indicating distribution into total body water.
Subcutaneous: approximately 90-100%. Oral: Very low (<2%) due to extensive presystemic metabolism by cholinesterases in the gastrointestinal tract and liver. Not administered orally. Inhalation: Variable, but effective locally; systemic absorption is minimal.
Oral: 75–85% (may be decreased with food); subcutaneous: nearly 100%.
No specific guidelines; use caution in severe renal impairment.
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: avoid use.
No specific guidelines; use caution in severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 50 mg twice daily; Child-Pugh C: avoid use.
Safety and efficacy not established; use not recommended.
Not recommended for use in pediatric patients.
Use with caution due to potential for increased sensitivity and comorbidities; consider starting at lower end of dosing range.
Initial dose 50 mg twice daily; titrate cautiously due to increased anticholinergic sensitivity.
Severe asthma or wheezing; administration to patients with asthma can cause fatal bronchospasm.
None.
Should be administered only by trained personnel; emergency resuscitative equipment must be immediately available; may cause bronchoconstriction, bradycardia, hypotension; use caution in patients with cardiovascular disease, epilepsy, hyperthyroidism, peptic ulcer, urinary obstruction.
Orthostatic hypotension (especially dose-related; syncope reported),Intraoperative floppy iris syndrome (IFIS) during cataract surgery,Priapism (rare),Dizziness, somnolence, and fatigue may occur,Use caution with hepatic impairment,Avoid use with strong CYP3A4 inhibitors or inducers
Asthma, COPD, severe cardiac disease, recent myocardial infarction, hypotension, hypertension, hyperthyroidism, epilepsy, Parkinson's disease, peptic ulcer, gastrointestinal or urinary obstruction, pregnancy (Category C).
Hypersensitivity to DUVOID or any component,Moderate to severe hepatic impairment (Child-Pugh class B or C),Use with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir)
Avoid caffeine-containing foods and beverages (coffee, tea, chocolate, cola) for at least 6 hours prior to bronchial challenge testing as they can affect airway reactivity.
Take on an empty stomach; food may decrease absorption. Avoid alcohol as it may increase cholinergic side effects.
Pregnancy Category C. Based on animal studies and limited human data, PROVOCHOLINE (methacholine) is not expected to increase the risk of major congenital malformations. However, bronchial provocation testing is generally avoided during pregnancy due to potential maternal hypoxia and fetal distress. First trimester: theoretical risk from maternal hypoxia; second and third trimesters: risk of preterm labor and fetal hypoxia if severe bronchospasm occurs.
DUVOID (bethanechol) is classified as FDA Pregnancy Category C. No adequate studies in pregnant women. Animal reproduction studies have not been conducted. Fetal risk cannot be ruled out. Use only if potential benefit justifies potential risk to fetus. No known specific trimester risks.
No human data on excretion in breast milk. Methacholine is rapidly hydrolyzed by plasma cholinesterases; systemic absorption after inhalation is minimal. M/P ratio is unknown. Caution is advised, but risk to nursing infant is likely low given rapid metabolism and low bioavailability.
It is not known whether bethanechol is excreted in human milk. Caution should be exercised when administered to a nursing woman. M/P ratio is unknown.
No specific dosing adjustments are recommended for methacholine challenge testing during pregnancy; however, the test is typically deferred due to potential risks. If conducted, start with lowest concentration (0.025 mg/m L) and titrate cautiously with close monitoring due to possible increased sensitivity of airway receptors and altered pharmacokinetics (increased plasma volume and decreased cholinesterase activity may prolong effects).
No formal pharmacokinetic studies in pregnancy. Due to increased plasma volume and renal clearance, dose adjustments may be necessary but specific recommendations are lacking. Use lowest effective dose and monitor clinical response.
Provocholine (methacholine chloride) is used for bronchial challenge testing to diagnose airway hyperreactivity in patients with suspected asthma but normal baseline spirometry. Administer with a nebulizer in increasing concentrations (0.025 to 25 mg/m L). Contraindicated in patients with FEV1 < 60% predicted, recent myocardial infarction, severe hypertension, or known hypersensitivity. Emergency resuscitation equipment must be available. Monitor for bronchospasm, oxygen desaturation, and treat with short-acting beta-agonists if needed.
DUVOID (bethanechol) is a cholinergic agonist used for urinary retention. Monitor for cholinergic crisis (excessive salivation, sweating, bradycardia). Administer on an empty stomach to reduce GI upset. Avoid in patients with asthma, hyperthyroidism, peptic ulcer disease, or epilepsy. Atropine is the antidote for overdose.
This test measures how sensitive your airways are to a substance that can cause narrowing.,You will inhale increasing doses of methacholine through a nebulizer while your breathing is tested.,Inform your doctor if you have asthma, recent heart attack, high blood pressure, or are pregnant.,Do not use caffeine or tobacco for at least 6 hours before the test.,Avoid using inhaler medications (e.g., albuterol) for 8-12 hours before the test as directed.,You may experience coughing, chest tightness, or shortness of breath during the test.,The test is stopped if your breathing drops significantly, and medication will be given to reverse effects.
Take this medication on an empty stomach, 1 hour before or 2 hours after meals.,Report any signs of excessive sweating, salivation, or bradycardia to your healthcare provider.,Avoid driving or operating machinery until you know how this drug affects you.,Do not stop taking this medication abruptly; consult your doctor for dose adjustments.,Keep a list of all medications you take and share with your healthcare provider.
"The serum concentration of Bupropion can be increased when it is combined with Choline."
"The therapeutic efficacy of Acemetacin can be decreased when used in combination with Choline."
"The serum concentration of Choline can be increased when it is combined with Tipiracil."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROVOCHOLINE vs DUVOID, answered by our medical review team.
PROVOCHOLINE is a Cholinergic Agonist that works by Parasympathomimetic agent that acts as a direct cholinergic agonist at muscarinic receptors, increasing exocrine gland secretion.. DUVOID is a Cholinergic Agonist that works by Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in the bladder neck and prostate, reducing outflow resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROVOCHOLINE and DUVOID depend on the specific clinical indication. These are both Cholinergic Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROVOCHOLINE is: Subcutaneous: 2.5-5 mg; if no response, repeat with 5-10 mg; maximum single dose 10 mg.. The standard adult dose of DUVOID is: 100 mg orally three times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROVOCHOLINE and DUVOID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROVOCHOLINE is classified as Category C. Pregnancy Category C. Based on animal studies and limited human data, PROVOCHOLINE (methacholine) is not expected to increase the risk of major congenital malformations. However, b. DUVOID is classified as Category C. DUVOID (bethanechol) is classified as FDA Pregnancy Category C. No adequate studies in pregnant women. Animal reproduction studies have not been conducted. Fetal risk cannot be rul. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.